24-166: A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06594991?viewType=Card&id=24-166&rank=1

Locations: Hartford Hospital and Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

Contact: Holly Maheu: holly.maheu@hhchealth.org